Related references
Note: Only part of the references are listed.Imaging Tumor Angiogenesis: The Road to Clinical Utility
Andrei Iagaru et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2013)
Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function
Yuhui Zou et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2013)
VEGF and Notch in Tip and Stalk Cell Selection
Raquel Blanco et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models
Cathy C. Zhang et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
Cathy C. Zhang et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma
V. Ramakrishnan et al.
LEUKEMIA (2012)
Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Qingbei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy
Hyunki Kim et al.
MOLECULAR IMAGING AND BIOLOGY (2011)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Nathalie Lassau et al.
CLINICAL CANCER RESEARCH (2010)
Cross-talk between Tumor and Endothelial Cells Involving the Notch3-DII4 Interaction Marks Escape from Tumor Dormancy
Stefano Indraccolo et al.
CANCER RESEARCH (2009)
Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
Leopoldo Luistro et al.
CANCER RESEARCH (2009)
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Rui Benedito et al.
CELL (2009)
Angiogenesis: A Team Effort Coordinated by Notch
L. -K. Phng et al.
DEVELOPMENTAL CELL (2009)
USEFULNESS OF HIF-1 IMAGING FOR DETERMINING OPTIMAL TIMING OF COMBINING BEVACIZUMAB AND RADIOTHERAPY
Guangfei Ou et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Notch Signal Activates Hypoxia Pathway through HES1-Dependent SRC/Signal Transducers and Activators of Transcription 3 Pathway
Jae Ho Lee et al.
MOLECULAR CANCER RESEARCH (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Multimodality molecular imaging of tumor angiogenesis
Weibo Cai et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Notch signaling regulates tumor angiogenesis by diverse mechanisms
J. Dufraine et al.
ONCOGENE (2008)
Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression
Carrie J. Shawber et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Notch signaling, gamma-secretase inhibitors, and cancer therapy
Ie-Ming Shih et al.
CANCER RESEARCH (2007)
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
John Ridgway et al.
NATURE (2006)
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T
Manickam Muruganandham et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Aberrant activation of Notch signaling in human breast cancer
S Stylianou et al.
CANCER RESEARCH (2006)
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
P Marzola et al.
CLINICAL CANCER RESEARCH (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Share Paper
